Since the 2007 recommendation, newer research also shows that individuals with ovarian cancer have pathogenic variants in genes other than BRCA1/2, and NCCN updated its guideline in 2016 to recommend a gene panel [26]. The gene discussed is BRCA1; the disease is ovarian cancer.